Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,792 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: cis Platinum Clear all
Completed Phase 2 Interventional Results available

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

NCT02412670
View directory record Official record
Conditions
High Grade Upper Tract Urothelial Carcinoma
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00057837
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
G-CSF, Cisplatin, Etoposide, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
79
States / cities
Lewes, Delaware • Newark, Delaware • Jacksonville, Florida + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 5:22 PM EDT
Active, not recruiting Phase 3 Interventional

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

NCT00734877
View directory record Official record
Conditions
Multiple Myeloma
Interventions
M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00062322
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

NCT00003322
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

NCT01588431
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

NCT00590031
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Cisplatin, Irinotecan, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

NCT00005051
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

NCT01005329
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Cisplatin, Intensity-Modulated Radiation Therapy, Paclitaxel
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
38
States / cities
Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

NCT00006105
View directory record Official record
Conditions
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 5:22 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 5:22 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT02567422
View directory record Official record
Conditions
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Berzosertib, Cisplatin, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
19
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00003242
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bryostatin 1, cisplatin, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 22, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

NCT02707666
View directory record Official record
Conditions
Pleural Mesothelioma
Interventions
Pembrolizumab, Cisplatin and Pemetrexed
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 22, 2026, 5:22 PM EDT
Recruiting Phase 1 Interventional

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

NCT07532902
View directory record Official record
Conditions
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
Interventions
BMS-986504, Ipilimumab, Nivolumab, 5-FU, Leucovorin, Oxaliplatin, Gemcitabine, Platinum
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 3 Interventional

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00003299
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

NCT00002813
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, vinorelbine tartrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Orange, California • Honolulu, Hawaii • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cisplatin, Doxorubicin, Methotrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 22, 2026, 5:22 PM EDT
Terminated Phase 1 Interventional Results available

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

NCT02083679
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine, Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed, Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel, Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

NCT02264990
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 22, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

NCT02402920
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

NCT07392580
View directory record Official record
Conditions
Laryngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Epinephrine injection, Laryngeal Biopsy, Endoscopic Surgery
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 5:22 PM EDT